Main Article Content
Effects of Co-administration of Moringa oliefera Leaf Tea with Standard Drug on Diabetic and Hypertensive Co-morbidity Patients
Abstract
Treatments of diabetes and hypertension have remained a great challenge due to complications of toxicities and drug resistance associated with the chemotherapeutic regimens. Hence the need to explore the use of supplements in the management of diabetic patients. This study aimed to evaluate the effects of Moringa oleifera leaf tea (MOT) supplements on the glucose and haematological parameters in diabetes and hypertension co-morbidity patients. Fifty (50) patients of either sex diagnosed with the comorbidity of diabetes and hypertension were randomly assigned into five groups each consisting of ten patients (n=10) each. Group 1 served as the positive control, Group 2 as the negative control, Group 3 received normal control treatment plus MOT , Group 4 was treated with a reference drug, and Group 5 received the reference drug in combination with MOT. Administration was done for 14 days and thereafter, blood samples were collected for the assay of advanced glycation end product (AGEs), Advanced Oxidation Protein Product (AOPP), Glucose Index (Random, fasting and post prandial blood sugars) and haematological indices. The result revealed a significant decrease (p<0.01) in the level of AGEs and AOPP among patients treated with MOT compared to patients served with standard drug only and groups treated with standard drugs and control. There was a significant (p<0.01) reduction in the haematological parameters of all the groups treated with the standard drugs. However, there was a significant increase in the haematological parameters of the groups co- administered with MOT when compared with the control groups with only standard drugs. In conclusion, co-administration of M. oleifera leaf tea to patients suffering from diabetes-hypertension comorbidity treatment regimens can mitigate the adverse effects of the drugs by the reduction of glycemic parameters while improving the haematological parameters.